5-ヒドロキシトリプタミン受容体2B治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:5-Hydroxytryptamine Receptor 2B - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0403
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

5-Hydroxytryptamine Receptor 2B – Pipeline Review, H2 2019
Summary

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report 5-Hydroxytryptamine Receptor 2B – Pipeline Review, H2 2019, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – 5-Hydroxytryptamine receptor 2B (5-HT2B) or serotonin receptor 2B is a protein encoded by the HTR2B gene. It plays a role in the regulation of behavior, including impulsive behavior. It protects cardiomyocytes against apoptosis. It plays a role in the adaptation of pulmonary arteries to chronic hypoxia and vasoconstriction. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Respiratory, Cardiovascular, Gastrointestinal, Immunology, Metabolic Disorders, Musculoskeletal Disorders, Oncology and Ophthalmology which include indications Drug Addiction, Attention Deficit Hyperactivity Disorder (ADHD), Idiopathic Pulmonary Fibrosis, Psychiatric Disorders, Psychosis, Pulmonary Arterial Hypertension, Schizophrenia, Systemic Sclerosis (Scleroderma), Alzheimer’s Disease, Autism, Binge Eating Disorder, Bipolar Disorder (Manic Depression), Carcinoid Syndrome (Malignant Carcinoid Syndrome), Chronic Obstructive Pulmonary Disease (COPD), Cirrhosis, Diarrhea, Fibrosis, Insomnia, Irritable Bowel Syndrome, Liver Fibrosis, Major Depressive Disorder, Neuroendocrine Tumors, Non-Alcoholic Steatohepatitis (NASH), Obesity, Obsessive-Compulsive Disorder, Ocular Hypertension, Open-Angle Glaucoma, Schizoaffective Disorder and Sedation.

Furthermore, this report also reviews key players involved in 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B)
- The report reviews 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics and enlists all their major and minor projects
- The report assesses 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – Overview
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – Companies Involved in Therapeutics Development
AnaMar AB
Daya Drug Discoveries Inc
INVENT Pharmaceuticals Inc
medac GmbH
Neurim Pharmaceuticals Ltd
RaQualia Pharma Inc
Reviva Pharmaceuticals Inc
Seropeutics LLC
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – Drug Profiles
AM-1476 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brilaroxazine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DDD-024 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INV-240 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piromelatine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00310941 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SERx-480 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize HTR2B for Fibrosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target 5HT2 for CNS Disorders and Obesity – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terguride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – Dormant Products
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – Discontinued Products
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – Product Development Milestones
Featured News & Press Releases
Jun 03, 2019: Reviva Pharmaceuticals announces successful completion of pre-IND meeting with FDA on Brilaroxazine for the treatment of idiopathic pulmonary fibrosis
Apr 10, 2018: Reviva Pharmaceuticals Receives FDA Orphan Designation for RP5063 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Oct 17, 2017: Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting With FDA on RP5063 for the Treatment of Pulmonary Arterial Hypertension
Mar 07, 2017: Phase II Clinical Trial for Treatment of Mild Alzheimer’s Disease
Nov 17, 2016: Reviva Pharmaceuticals Receives FDA Orphan Designation for Pulmonary Arterial Hypertension (PAH)
Sep 28, 2016: Neurim Pharmaceuticals Announces First Patients Enrollments in ReCOGNITION – Phase II Clinical Trial of Piromelatine for Mild Alzheimers Disease
May 19, 2016: Reviva Pharmaceuticals Presented RP5063 Preclinical Efficacy Results for Pulmonary Arterial Hypertension at the American Thoracic Society Conference 2016
Apr 20, 2016: RaQualia Receives a Patent Allowance for 5-HT 2B Antagonist in Korea
Oct 22, 2015: Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits
Jun 01, 2015: RaQualia to Initiate Phase I Clinical Trial for 5-HT2B Antagonist in UK
Aug 20, 2014: RaQualia Receives a Patent Allowance for 5-HT2B Antagonist in Japan
Nov 05, 2013: Reviva Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA for RP5063
Jul 11, 2013: Novel antipsychotic shows early promise
Apr 09, 2013: Reviva Pharma Reports Positive Top-Line Results From Phase II Study Of RP5063 For Treatment Of Schizophrenia And Schizoaffective Disorder
Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AnaMar AB, H2 2019
Pipeline by Daya Drug Discoveries Inc, H2 2019
Pipeline by INVENT Pharmaceuticals Inc, H2 2019
Pipeline by medac GmbH, H2 2019
Pipeline by Neurim Pharmaceuticals Ltd, H2 2019
Pipeline by RaQualia Pharma Inc, H2 2019
Pipeline by Reviva Pharmaceuticals Inc, H2 2019
Pipeline by Seropeutics LLC, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

【掲載企業】

AnaMar AB
Daya Drug Discoveries Inc
INVENT Pharmaceuticals Inc
medac GmbH
Neurim Pharmaceuticals Ltd
RaQualia Pharma Inc
Reviva Pharmaceuticals Inc
Seropeutics LLC

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[5-ヒドロキシトリプタミン受容体2B治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆